HIGHLIGHTS
- who: W. Timothy Garvey from the (UNIVERSITY) have published the paper: Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial, in the Journal: (JOURNAL) of 30/03/2022
SUMMARY
The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term treatment of adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes. The mean change in body weight from baseline to week 104 was -15.2% in the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.